Primenenie kholina al'fostserata i ego kombinatsii s etilmetilgidroksipiridina suktsinatom v terapii somaticheskikh bol'nykh s kognitivnymi rasstroystvami


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The presently observed increase in life expectancy has led to the aging of the population and as a consequence - to increase the prevalence of somatic diseases and cognitive disorders, which requires new approaches to their treatment. The feasibility of use of choline alfoscerate and ethylmethylhydroxypyridine succinate in cognitive disorders is justified. The clinical data confirming the high efficacy of the combination of choline alfoscerate and ethylmethylhydroxypyridine succinate in patients with cerebrovascular diseases accompanied by cognitive disorders are presented. Potentially, this combination may be useful to improve the physical and cognitive status of critically ill patients, cardiac patients, patients with diabetes and metabolic syndrome.

全文:

受限制的访问

参考

  1. Mavrodaris A., Powell J., Thorogood M. Prevalences of dementia and cognitive impairment among older people in sub-Saharan Africa: a systematic review// Bull. World Health Organ. -2013. - Vol. 91(10). - P. 773-83.
  2. Lobo A., Launer L.J., Fratiglioni L., et al. Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group // Neurology. - 2000. - Vol. 54(11 Suppl. 5). - S4-9.
  3. World Alzheimer report 2009 London: Alzheimer's Disease International; 2009.
  4. Захаров В.В., Яхно Н.Н. Синдром умеренных когнитивных расстройств в пожилом возрасте: диагностика и лечение // РМЖ. - 2004. - № 10. - C. 573-76.
  5. Galvin J.E. Optimizing diagnosis and manange-ment in mild-to-moderate alzheimer's disease // Neurodegener. Dis. Manag. - 2012. -Vol. 2(3). - P. 291-304.
  6. Gardner R.C., Valcour V., Yaffe K. Dementia in the oldest old: a multi-factorial and growing public health issue // Alzheimers Res. Ther. -2013. - Vol. 5(4). - P. 27.
  7. Захаров В.В., Яхно Н.Н. Когнитивные расстройства в пожилом и старческом возрасте. Методическое пособие для врачей. М., 2005. - 71 с.
  8. Маркин С.П. Нарушение когнитивных функций во врачебной практике. Воронеж, 2007
  9. Wilcox M.E., Brummel N.E., Archer K., et al. Cognitive dysfunction in ICU patients: risk factors, predictors, and rehabilitation interventions // Crit. Care Med. - 2013. - Vol. 41(9 Suppl. 1). -S81-98.
  10. Wadley V.G., McClure L.A., Howard V.J., et al. Cognitive status, stroke symptom reports, and modifiable risk factors among individuals with no diagnosis of stroke or transient ischemic attack in the REasons for Geographic and Racial Differences in Stroke (REGARDS) Study // Stroke. -2007. - Vol. 38(4). - P. 1143-47.
  11. Yeh Y.C., Liu.CL., Peng L.N., et al. Potential benefits of reducing medication-related anticholinergic burden for demented older adults: a prospective cohort study // Geriatr. Gerontol. Int. - 2013. - Vol. 13(3). - P. 694-700.
  12. Albert M.S., DeKosky S.T., Dickson D., et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Ageing-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease // Alzheimers Dement. - 2011. - Vol. 7. - P. 270-79.
  13. Бурчинский С.Г. Возможность достижения сочетанного когнитивного и анксиолитического эффектов как новое направление фармакотерапии в ангионеврологии // Consilium medicum ukraina. - 2010. - № 4.
  14. The global burden of disease: 2004 update Geneva: World Health Organization; 2008.
  15. Alzheimer's Association 2012 Alzheimer's Disease Facts and Figures Alzheimer's and Dementia: http://www.alz.org/downloads/ Facts_Figures_2012.pdf.
  16. Williams J.W., Plassman B.L., Burke J., Holsinger T., Benjamin S. Agency for Healthcare Research and Quality. U.S. Department of Health and Human Services; Apr, 2010. Preventing Alzheimer's disease and cognitive decline. AHRQ Publication No. 10-E005.
  17. Preventing Alzheimer's Disease and Cognitive Decline. NIH State-of-the-Science Conference April 26-28, 2010. Bethesda, Maryland Final Panel Statement.
  18. Morris M.C. The role of nutrition in Alzheimer's disease: epidemiological evidence // Eur. J. Neurol. - 2009. - Vol. 16(Suppl. 1). - P. 1-7.
  19. Yeh Y.C., Liu C.L., Peng L.N., et al. Potential benefits of reducing medication-related anticholinergic burden for demented older adults: a prospective cohort study // Geriatr. Gerontol. int. - 2013. - Vol. 13(3). - P. 694-700.
  20. Fortin M.P., Rouch i, Dauphinot V., et al. Effects of anticholinergic drugs on verbal episodic memory function in the elderly: a retrospective, crosssectional study// Drugs Aging. - 2011/ - Vol. 28. - P. 195-204.
  21. Campbell N., Boustani M., Limbil T., et al. The cognitive impact of anticholinergics: a clinical review // Clin. interv. Aging. - 2009. -Vol. 4. - P. 225-33.
  22. Sink K.M., Leng X., Williamson J., et al. Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study // Arch. intern. Med. - 2009. - Vol. 169(13). - P. 1195-202.
  23. Zuccala G., Onder G., Pedone C., et al. Hypotension and cognitive impairment: selective association in patients with heart failure // Neurology. - 2001. - Vol. 57. - P. 1986-92.
  24. Davies N.M., Kehoe P.G., Ben-shlomo Y., Martin R.M. Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias // J. Alzheimers Dis. - 2011. - Vol. 26. - P. 699-708.
  25. Solfrizzi V., Scafato E., Frisardi V., et al. Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The italian Longitudinal Study on Aging // Age (Dordr). - 2013. - Vol. 35(2). - P. 441-53.
  26. Beishon L.C., Harrison J.K., Harwood R.H., et al. The evidence for treating hypertension in older people with dementia: a systematic review // J. Hum. Hypertens. - 2013. - Nov 7. [Epub ahead of print].
  27. FDA Drug Safety Communication: important safety label changes to cholesterol-lowering statin drugs http://www.fda.gov/Drugs/ DrugSafety/ucm293101.htm
  28. Richardson K., Schoen M., French B., et al. Statins and cognitive function: a systematic review // Ann. intern. Med. - 2013. - Vol. 159(10). - P. 688-97.
  29. Brown S. Ginkgo biloba no better than placebo in preventing dementia // Menopause int. - 2012. - Vol. 18(4). - P. 125.
  30. DeKosky S.T., Williamson J.D., Fitzpatrick A.L., et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial// JAMA. - 2008. - Vol. 300(19). - P. 2253-62.
  31. Snitz B.E., O'Meara E.S., Carlson M.C. Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial // JAMA. - 2009. - Vol. 302(24). - P. 2663-70.
  32. Mayeux R. Clinical practice. Early Alzheimer's disease // N. Engl. J. Med. - 2010. - Vol. 362. - P. 2194-201.
  33. Nordstr m P, Religa D., Wimo A., et al. The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer's disease// Eur. Heart J. - 2013. - Vol. 34(33). - P. 2585-91.
  34. Takeda M. [Molecular pathogenesis and development of disease-modifying drugs for Alzheimer's disease // Seishin Shinkeigaku Zasshi. - 2013. - Vol. 115(1). - P. 32-40.
  35. Hrabovska A, Krejci E. Reassessment of the Role of the Central Cholinergic System // J. Mol. Neurosci. - 2013. - Nov 10. [Epub ahead of print].
  36. Traini E., Bramanti V., Amenta F. Choline Alphoscerate (alpha-glyceryl-phosphoryl-choline) an Old Choline-containing Phospholipid with a still interesting Profile as Cognition Enhancing Agentn// Curr. Alzheimer Res. -2013. - Oct 23. [Epub ahead of print].
  37. Scapicchio P.L. Revisiting choline alphoscerate profile: a new, perspective, role in dementia?// int. J. Neurosci. - 2013. - Vol. 123(7). - P. 444-49.
  38. Meck W.H., Williams C.L. Metabolic imprinting of choline by its availability during gestation: implications for memory and attentional processing across the lifespan // Neurosci. Biobehav. Rev. - 2003. - Vol. 27(4). - P. 385-99.
  39. Ramanan V.K., Saykin A.J. Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders // Am. J. Neurodegener. Dis. - 2013. - Vol. 2(3). - P. 145-75.
  40. Giacobini E. Cholinergic foundations of Alzheimer'sdiseasetherapy//J. Physiol. (Paris). - 1998. - Vol. 92. - P. 283-87.
  41. Nashmi R., Dickinson M.E., McKinney S., et al. Assembly of alpha4beta2 nicotinic acetylcholine receptors assessed with functional fluorescently labeled subunits: effects of localization, trafficking, and nicotine-induced upregulation in clonal mammalian cells and in cultured midbrain neurons//J. Neurosci. - 2003. - Vol. 23(37). - P. 11554-67.
  42. Giacobini E. Cholinergic function and Alzheimer's disease // int. J. Geriatr. Psych. - 2003. - Vol. 18 - S1-S5.
  43. O'Neill M.J., Murray T.K., Lakics V., Visanji N.P., Duty S. The Role of Neuronal Nicotinic Acetylcholine Receptors in Acute and Chronic Neurodegeneration. Current Drug Targets // CNS Neurol. Dis. - 2002. - Vol.1(4). - P. 399-411.
  44. Nitsch R., Pittas A., Blusztajn J.K., et al. Alterations of phospholipid metabolites in postmortem brain from patients with Alzheimer's disease // Ann. N Y Acad. Sci. - 1991. - Vol. 640. - P. 110-13.
  45. Whiley L., Sen A., Heaton J., et al. Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease // Neurobiol. Aging. - 2014. - Vol. 35(2). - P. 271-78.
  46. Tumati S., Martens S., Aleman A. Magnetic resonance spectroscopy in mild cognitive impairment: Systematic review and meta-analysis // Neurosci. Biobehav. Rev. - 2013. - Aug 19. [Epub ahead of print]
  47. Yang X., Sheng W., He Y., et al. Secretory phospholipase A2 type iii enhances alpha-secretase-dependent amyloid precursor protein processing through alterations in membrane fluidity // J. Lipid. Res. - 2010. - Vol. 5. - P. 957-66.
  48. Brender J.R., Lee E.L., Cavitt M.A., et al. Amyloid fiber formation and membrane disruption are separate processes localized in two distinct regions of iAPP, the type-2-diabetes-related peptide // J. Am. Chem. Soc. - 2008. - Vol. 130. - P. 6424-29.
  49. Klein J. Membrane breakdown in acute and chronic neurodegeneration: focus on choline-containing phospholipids // J. Neural. Transm. - 2000. - Vol. 107. - P. 1027-63.
  50. Tayebati S.K., Amenta F. Choline-containing phospholipids: relevance to brain functional pathways // Clin. Chem. Lab. Med. - 2013. -Vol. 51(3). - P. 513-21.
  51. Ueland P.M. Choline and betaine in health and disease // J. inherit. Metab. Dis. - 2011. - Vol. 34(1). - P. 3-15.
  52. Zeisel S.H. The fetal origins of memory: the role of dietary choline in optimal brain development// J. Pediatr. - 2006. - Vol. 149(5 Suppl.). -S131-36.
  53. Nyaradi A., Li J., Hickling S., Foster J., Oddy W.H. The role of nutrition in children's neurocognitive development, from pregnancy through childhood // Front Hum. Neurosci. - 2013. - Vol. 7. - P. 97.
  54. Niculescu M.D., Craciunescu C.N., Zeisel S.H. Dietary cholin deficiency alters global and gene-specific DNA methylation in the developing hippocampus of mouse fetal brains // FASEB J. - 2006. - Vol. 20. - P. 43-9.
  55. Нетребенко О.К. Влияние питания на развитие мозга // Педиатрия. - 2008. - Т. 87. -№ 3. -С. 96-103.
  56. Cheng R.K., MacDonald C.J., Williams C.L., Meck WH. Prenatal choline supplementation alters the timing, emotion, and memory performance (TEMP) of adult male and female rats as indexed by differential reinforcement of low-rate schedule behavior // Learn. Mem. - 2008. - Vol. 15. - P. 153-62
  57. Glenn M.J., Kirby E.D., Gibson E.M., et al. Age-related declines in exploratory behavior and markers of hippocampal plasticity are attenuated by prenatal choline supplementation in rats // Brain Res. - 2008. - Vol. 1237. - P. 110-23.
  58. Zeisel S.H. The supply of choline is important for fetal progenitor cells // Semin. Cell Dev. Biol. - 2011. - Vol. 22(6). - P. 624-28.
  59. Wong-Goodrich S.J., Glenn M.J., Mellott T.J., et al. Spatial memory and hippocampal plasticity are differentially sensitive to the availability of choline in adulthood as a function of choline supply in utero // Brain Res. - 2008. - Vol. 1237. - P. 153-66.
  60. Yan J, Jiang X., West A.A., et al. Maternal choline intake modulates maternal and fetal biomarkers of choline metabolism in humans // Am. J. Clin. Nutr. - 2012. - Vol. 95(5). - P. 1060-71.
  61. Boeke C.E., Gillman M.W., Hughes M.D., et al. Choline intake during pregnancy and child cognition at age 7 years // Am. J. Epidemiol. - 2013. - Vol. 177(12). - P. 1338-47.
  62. Wu B.T., Dyer R.A., King D.J., et al. Early second trimester maternal plasma choline and betaine are related to measures of early cognitive development in term infants // PLoS One. - 2012. -Vol. 7(8). - e43448.
  63. Wecker L. Dietary choline: a limiting factor for the synthesis of acetylcholine by the brain // Adv. Neurol. - 1990. -Vol. 51. - P. 139-45.
  64. Thal L.J. Cholinomimetic treatment of Alzheimer's disease//Prog. Brain Res. - 1996. -Vol. 109. - P. 299-309.
  65. Amenta F., Parnetti L., Gallai V., Wallin A. Treatment of cognitive dysfunction associated with Alzheimer's disease with cholinergic precursors. Ineffective treatments or inappropriate approaches? // Mech. Ageing Dev. - 2001. -Vol. 122. - P. 2025-40.
  66. Higgins J.P., Flicker L. Lecithin for dementia and cognitive impairment // Cochrane Database Syst. Rev. - 2003:CD001015.
  67. Ilcol Y.O., Ozbek R., Hamurtekin E., Ulus I.H. Choline status in newborns, infants, children, breast-feeding women, breast-fed infants and human breast milk//J. Nutr. Biochem. - 2005. -Vol. 16(8). - P. 489-99.
  68. Liu H.C., Chi C.W., Liu T.Y., et al. Effect of aging on phosphate metabolites of rat brain as revealed by the in vivo and in vitro 31P NMR measurements // Life Sci. - 1991. - Vol. 48(21). - P. 2057-63.
  69. Черний В.И. Холина альфосцерат: современный взгляд на возможности лечения острой церебральной недостаточности // Здоров'яУкраїни. Тематичнийномер.-2011.-№ 1.
  70. Bramanti V., Bronzi D., Tomassoni D., et al. Effect of choline-containing phospholipids on transglutaminase activity in primary astroglial cell cultures // Clin. Exp. Hypertens. - 2008. -Vol. 30(8). - P. 798-807.
  71. Kawamura T., Okubo T., Sato K., et al. Glycerophosphocholine enhances growth hormone secretion and fat oxidation in young adults // Nutrition. - 2012. - Vol. 28(11-12). -P. 1122-26.
  72. Sigala S., Imperato A., Rizzonelli P., et al. L-alpha-glycerylphosphorylcholine antagonizes scopolamine-induced amnesia and enhances hippocampal cholinergic transmission in the rat // Eur. J. Pharmacol. - 1992. - Vol. 211. -P. 351-58.
  73. Parnetti L., Abate G., Bartorelli L., et al. Multicentre study of l-alpha-glyceryl-phosphorylcholine vs. ST200 among patients with probable senile dementia of Alzheimer's type // Drugs Aging. - 1993. - Vol. 3. - P. 159-64.
  74. De Jesus Moreno M. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial // Clin. Ther. - 2003. - Vol. 25. - P. 178-93.
  75. Barbagallo Sangiorgi G., Barbagallo M., Giordano M., et al. Alpha-glycerophosphocholine in the mental recovery of cerebral ischemic attacks. An Italian multicenter clinical trial // Ann. NY Acad. Sci. - 1994. - Vol. 717. - P. 253-69.
  76. Levin O.S., Batukaeva L.A., Anikina M.A., Yunishchenko N.A. Efficacy and safety of choline alphoscerate (cereton) in patients with Parkinson's disease with cognitive impairments // Neurosci. Behav. Physiol. - 2011. -Vol. 41. - P. 47-51.
  77. Исмагилов М.Ф., Василевская О.В., Гайфутдинов Р.Т. и др. Оценка эффективности церетона в остром периоде ишемического инсульта // Журн. неврол и психиатр им. С.С. Корсакова. - 2009. - № 3. - С. 35.
  78. Стулин И.Д., Мусин Р.С., Солонский Д.С. Эффективность холина альфосцерата (церетон) у больных с хронической ишемией мозга // Журн. неврол и психиатр им. С.С. Корсакова. -2009. - № 7. - С. 87-9.
  79. Parnetti L., Mignini F., Tomassoni D., et al. Cholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approaches or need for re-evaluation? // J. Neurol. Sci. - 2007. - Vol. 257. - P. 264-69.
  80. Ушкалова А.В. Депрессии в общесоматической пратике: эпидемиология, скрининг, диагностика и фармакотерапия // Фарматека. - 2006. - № 7. - С. 28-36.
  81. Li Z., Vance D. Phosphatidylcholine and choline homeostasis // J. Lipid. Res. - 2008. - Vol. 49. -P. 1187-94.
  82. Amenta F., Carotenuto A., Fasanaro A.M., Rea R., Traini E. The ascomalva trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscer-ate in Alzheimer's disease with cerebrovascular injury: interim results // J. Neurol. Sci. - 2012. -Vol. 322. - P. 96-101.
  83. Бадалян О.Л., Савенков А.А., Таншева К.Х. , Тертышник О.Ю. Возможности применения нейрокса в комплексном лечении хронической ишемии мозга // РМЖ. - 2010. -Т. 18. - № 8. - С. 455-59.
  84. Меньщикова Е.Б., Зенков Н.К., Ланкин В.З., Бондарь И.А., Труфакин В.А. Окислительный стресс: Патологические состояния и заболевания. Издательство: АРТА, 2008.
  85. Бадалян О.Л., Погосян А.С., Савенков А.А., Таишева К.Х., Тертышник О.Ю. Применение препаратов Нейрокс® и Церетон® в комплексном лечении цереброваскулярных заболеваний // РМЖ. - 2011. - № 12. - С. 764-78.
  86. Бадалян О.Л. Влияние комбинированного применения карбамазепина и антиоксидантов на эпилептическую систему. Дисс. канд. мед. наук. М., 1998.
  87. Никифоров А.С., Коновалов А.Н., Гусев Е.И. Клиническая неврология. М., 2002.
  88. Верижникова Е.В., Шоломов И.И., Дорошенко Л.М. Применение препарата "Мексидол" в интенсивной терапии пациентов с мультиорганной недостаточностью // Бюллетень экспериментальной биологии и медицины. - 2006. - Прил. 1. -С. 104.
  89. Булахова Е.Ю. Использование препарата "Мексидол" для оптимизации лечения артериальной гипертензии у больных молодого возраста // Бюллетень экспериментальной биологии и медицины. - 2006. - Прил. 1. - С. 101.
  90. Одинцова Н.Ф. Мексидол в комплексной терапии артериальной гипертензии у больных пожилого и старческого возраста. Дисс. канд. мед. наук. Ижевск, 2007.
  91. Баженова Л.Н., Володина Н.Н., Фролова Н.П. Влияние препарата «Мексидол» на эндотелиальную дисфункцию у больных с хронической сердечной недостаточностью // Бюллетень экспериментальной биологии и медицины. - 2006. - Прил. 1. - С. 96.
  92. Занозина О.В., Боровков Н.Н., Балаболкин М.И. и др. Необходимость и достаточность использования антиоксидантов в терапии больных сахарным диабетом 2-го типа // Бюллетень экспериментальной биологии и медицины. - 2006. - Прил. 1. -С. 112.
  93. Местер Н.В. Влияние производных 3-оксипиридина на когнитивные функции и аффективный статус больных сахарным диабетом. Дисс. канд. мед. наук. Челябинск, 2007.
  94. Мазуров В.И., Болотова М.Е. Роль и место Мексидола в лечении метаболического синдрома // РМЖ. - 2008. - № 15. -C. 1024-28.
  95. Симонова Ю.В., Головкин В.И., Камынин Ю.Ф. Коррекция метаболического синдрома у больных рассеянным склерозом с помощью мексидола // Бюллетень экспериментальной биологии и медицины. - 2006. - Прил. 1. -С. 82
  96. Малышев В.Е., Сальникова О.И. Опыт применения препарата «Мексидол» в комплексном амбулаторном лечении больных с заболеваниями глаз дегенеративнодистрофического происхождения // Бюллетень экспериментальной биологии и медицины. - 2006. - Прил. 1. - С. 55.
  97. Шмырев В.И., Крыжановский С.М. Комбинированная терапия ишемического инсульта холина альфосцератом и этилметилгидроксипиридина сукцинатом // Фарматека. - 2013. - № 9. - С. 79-83.
  98. Серегин В.И. Применение Глиатилина и Мексидола в интенсивной терапии тяжелого острого ишемического инсульта // Фарматека. - 2006. - № 5.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##